BANK OF MONTREAL /CAN/ - CRISPR THERAPEUTICS AG ownership

CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 414 filers reported holding CRISPR THERAPEUTICS AG in Q4 2020. The put-call ratio across all filers is 1.10 and the average weighting 0.3%.

Quarter-by-quarter ownership
BANK OF MONTREAL /CAN/ ownership history of CRISPR THERAPEUTICS AG
ValueSharesWeighting
Q3 2023$267,243
-17.1%
5,237
-3.6%
0.00%
Q2 2023$322,187
+21.6%
5,435
+39.2%
0.00%
Q3 2022$265,000
-15.3%
3,904
-7.3%
0.00%
Q2 2022$313,000
-96.0%
4,213
-96.5%
0.00%
-100.0%
Q1 2022$7,745,000
+1850.9%
119,955
+2322.4%
0.00%
Q4 2021$397,000
-4.6%
4,952
+34.0%
0.00%
Q3 2021$416,000
+7.5%
3,696
+39.3%
0.00%
Q2 2021$387,000
+126.3%
2,654
+86.6%
0.00%
Q1 2021$171,000
-59.6%
1,422
-36.5%
0.00%
Q4 2020$423,000
+10475.0%
2,238
+4562.5%
0.00%
Q3 2020$4,000
-95.6%
48
-95.0%
0.00%
Q2 2020$90,000
-3.2%
957
-59.5%
0.00%
Q1 2020$93,000
-97.2%
2,364
-95.7%
0.00%
-100.0%
Q4 2019$3,357,000
-6.6%
55,114
-37.1%
0.00%
-33.3%
Q3 2019$3,595,000
-35.0%
87,680
-25.3%
0.00%
-25.0%
Q2 2019$5,528,000
+61.2%
117,360
+22.2%
0.00%
+33.3%
Q1 2019$3,429,000
+27.2%
96,010
+1.8%
0.00%0.0%
Q4 2018$2,695,000
-39.2%
94,320
-5.6%
0.00%0.0%
Q3 2018$4,432,000
-18.5%
99,933
+7.9%
0.00%
-25.0%
Q2 2018$5,440,000
+166.0%
92,583
+107.0%
0.00%
+100.0%
Q1 2018$2,045,000
+4444.4%
44,733
+2208.2%
0.00%
Q4 2017$45,000
+32.4%
1,9380.0%0.00%
Q3 2017$34,000
+30.8%
1,938
+18.3%
0.00%
Q2 2017$26,000
-27.8%
1,6380.0%0.00%
Q1 2017$36,0001,6380.00%
Other shareholders
CRISPR THERAPEUTICS AG shareholders Q4 2020
NameSharesValueWeighting ↓
Versant Venture Management, LLC 498,558$31,294,00031.24%
NEA Management Company, LLC 1,590,002$365,593,00010.56%
Ariose Capital Management Ltd 37,900$2,379,0009.30%
ARK Investment Management 9,404,071$590,294,0002.46%
NIA IMPACT ADVISORS, LLC 80,082$5,027,0002.44%
Nikko Asset Management Americas, Inc. 4,619,747$291,044,0002.14%
PLUSTICK MANAGEMENT LLC 50,000$3,139,0001.98%
Integral Health Asset Management, LLC 120,000$7,532,0001.96%
Valiant Capital Management, L.P. 240,683$15,108,0001.73%
Deuterium Capital Management, LLC 18,000$1,130,0001.45%
View complete list of CRISPR THERAPEUTICS AG shareholders